【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於有瞻妄風險之老年人。

Endocrine and rheumatic disorders, collagen, dermatological, ophthalmic, respiratory and GI disease, exacerbation of multiple sclerosis, nephrotic syndrome, allergic states

Prednisolone is a synthetic adrenocorticosteroid that mainly exerts glucocorticoid effects like promotion of gluconeogenesis, increased deposition of glycogen in the liver, inhibition of utilization of glucose, anti-insulin activity, increased catabolism of protein, increased lipolysis, stimulation of fat synthesis and storage, and increased urate and calcium excretion. Prednisolone reduces eosinophils and lymphocytes production, stimulates erythropoiesis and polymorphonuclear leukocytes production and inhibits inflammatory processes and wound healing. Prednisolone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotrophin may lead to suppression of endogenous corticosteroids.

Duration：18-36 hr; Absorption：rapidly and well absorbed; plasma protein binding：70-90%; Metabolism：liver ; Eliminated half-life : 2-4 hr.

Systemic fungal infections; hypersensitivity to the drug or any of its components; administration of live virus vaccines in patients receiving immunosuppressive corticosteroid doses

C

Probably safe, breast- feeding appears to be safe with maternal dose ≦20 mg daily or large doses for short periods. It is suggested that nursing be performed 3-4 hours after the dose.

increased appetite, weight gain, impaired wound healing, thin fragile skin, peptic ulcer, at risk of infection, hypertension, hyperglycemia, fluid and salt retention, potassium loss, adrenal insufficiency, Cushing’s syndrome, osteoporosis, cataract, glaucoma, steroid psychoses.

5~ 60 mg per day depending on the specific disease entity being treated

0.14~2 mg/kg/day in three or four divided doses, depending on the specific disease entity being treated.